Investors are increasingly turning their eyes toward the healthcare sector, recognizing a significant opportunity within what many consider a lagging market. Analysts from Morgan Stanley recently highlighted this sentiment during an episode of their “Thoughts on the Market” podcast, noting that healthcare is on the brink of a potential rebound despite mixed performance indicators in early 2025.
The healthcare sector has shown signs of momentum, particularly through the iShares US Healthcare ETF, which climbed 2.9% in October. However, broader measures illustrate a more subdued annual performance; healthcare stocks within the S&P 500 have only gained 4.8% year-to-date, starkly trailing the 15.9% increase of the overall index, according to Select Sector SPDRs.
Several bullish factors are supporting a more optimistic outlook for the healthcare market, as explained by analysts Sean Laaman and Terence Flynn.
One key aspect is the sector’s insulation from tariffs. A growing number of companies within the biopharma and biotech areas are making substantial investments in U.S. manufacturing, indicating a strategic move to reshore supply chains and reduce exposure to global trade issues. Notably, Eli Lilly announced a $27 billion plan to build new manufacturing plants in the U.S., while AstraZeneca revealed intentions to invest $50 billion toward manufacturing and research & development in the country.
Additionally, the landscape for drug pricing has shifted, following an executive order signed by President Trump aimed at reducing prescription drug costs by as much as 80%. Although initial investor concerns loomed over the implications of this initiative, Flynn pointed out recent agreements forged by firms such as Pfizer and AstraZeneca with the administration, which may alleviate some uncertainties. The focus remains on whether further agreements will emerge.
Another factor influencing market dynamics is the impending wave of patent expirations, valued at approximately $177 billion in the large-cap biopharma sector by the decade’s end. Such expirations often prompt companies to bolster their competitive edge through mergers and acquisitions, a trend that had slowed in the first half of 2025 but is now seeing a rebound. Data from LevinPro HC indicates that M&A activity in healthcare rose 7% in the third quarter.
Moreover, the integration of artificial intelligence (AI) within the healthcare sector is expected to unlock new efficiencies. Laaman noted benefits like accelerated recruitment for clinical trials and expedited regulatory submissions as promising developments.
Lastly, a closer look at valuations reveals that the healthcare sector is currently trading at a price-to-earnings multiple about 30% lower than the S&P 500 average, suggesting that stocks in this arena are relatively undervalued. Flynn underscored that investment positioning in healthcare appears to remain light, further supporting the notion of an impending upswing.
In summary, the combination of strategic investments in domestic manufacturing, clarity in drug pricing, upcoming patent expirations, potential AI advancements, and attractive valuations is setting the stage for a healthcare sector rebound that investors are keenly watching.
